ACCEL Lite: Behind the ACC 2023 Guideline for Chronic CAD: Conversations and Controversies

Experts discuss key principles and the importance of risk-based treatment decisions in the ACC 2023 guideline for chronic coronary disease. They also delve into the signs and symptoms that prompt testing for chronic CAD and the impact of new therapies on patient management. The podcast covers recommendations for clinicians to avoid ineffective procedures and therapies, as well as class three recommendations for hormone replacement therapy and certain supplements. Additionally, they address the difficulty of persuading patients about the necessity of repeated testing and emphasize the importance of building trust through clear communication.